Homburger advised Credit Suisse Group on the completion on May 14, 2021 of the issuance of USD 3.25 bn 3.091% Fixed Rate/Floating Rate Senior Callable Notes due 2032 under its U.S. Senior Debt Program. The Notes are bail-inable
Tags :Homburger
The Goldman Sachs Group issued CHF 450 m Bonds on May 11, 2021. Credit Suisse – advised by Homburger – acted as lead manager, together with Commerzbank Aktiengesellschaft and Goldman Sachs International. The bonds will be listed on the Six
Homburger acted as legal counsel for Zürcher Kantonalbank in the issuance of EUR 500 m 0.00 per cent senior bonds due May 15, 2026. Homburger team was led by partner Benjamin Leisinger (Capital Markets, pictured) and included counsel
Homburger advised Santhera Pharmaceuticals Holding on the settlement of its first exchange offer for a convertible bond in Switzerland. Holders of current Santhera CHF 60 Unsecured Convertible Bonds due in 2022 have received new CHF 30,270,375 Senior Unsecured
PolyPeptide Group AG, a global operator in peptide development and manufacturing, successfully priced its initial public offering (IPO) at CHF 64 per share, implying a market capitalization of CHF 2.12 bn. The base offering of the IPO
New York Life Global Funding issued CHF 475 m Bonds in the form of a GIC bond. Credit Suisse AG acted as lead manager, together with Deutsche Bank AG London Branch, acting through Deutsche Bank AG
Homburger advised Telemos Capital on its acquisition of leading Swiss outdoor brand Mammut from Swiss holding company Conzzeta, advised by Baker McKenzie. Subject to obtaining all necessary regulatory approvals, the closing of the acquisition of
Dufry One launched successfully completed the issuance of CHF 300 m 3.625% Senior Notes due 2026 and EUR 725 m 3.375% Senior Notes due 2028. The Senior Notes are guaranteed by Dufry and certain of its subsidiaries. It is expected that
Credit Suisse Group announced the placement of two series of mandatory convertible notes due 2021, which will be issued through a Guernsey finance vehicle and convertible into a total of 203 million shares of, and guaranteed by,
Grünenthal announced the acquisition of Mestex through the purchase of all of its shares and outstanding options. Mestex is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the